Skip to main content

Table 1 Baseline clinical features

From: Development and validation of a prognostic nomogram in gastric cancer with hepatitis B virus infection

Characteristics Development cohort (n = 235) Validation cohort (n = 84)
Mean ± SD/No (%) Mean ± SD/No (%)
Age, year 54.95 ± 11.92 55.00 ± 11.58
Sex
 Male 163 (69.36%) 60 (71.43%)
 Female 72 (30.64%) 24 (28.57%)
TNM stage
 I 43 (18.30%) 6 (7.14%)
 II 66 (28.09%) 18 (21.43%)
 III 83 (35.32%) 37 (44.05%)
 IV 43 (18.30) 23 (27.38%)
Tumor stage
 T1 42 (17.87%) 6 (7.14%)
 T2 25 (10.64%) 5 (5.95%)
 T3 76 (32.34%) 29 (34.52%)
 T4 92 (39.15%) 44 (52.38%)
Node stage
 N0 62 (26.38%) 15 (17.86%)
 N1 41 (17.45%) 12 (14.29%)
 N2 43 (18.30%) 17 (20.24%)
 N3 89 (37.87%) 40 (47.62%)
Metastasis
 No 192 (81.70%) 61 (72.62%)
 Yes 43 (18.30%) 23 (27.38%)
Location
 1 33 (14.04%) 14 (16.67%)
 2 56 (23.83%) 23 (27.38%)
 3 109 (46.38%) 32 (38.10%)
 4 37 (15.74%) 15 (17.86%)
AST, U/L
 ≤ 22.8 17.51 ± 2.66 17.65 ± 3.70
 > 22.8 35.15 ± 21.05 44.82 ± 34.85
ALT, U/L
 ≤ 30.1 16.67 ± 5.37 17.89 ± 5.94
 > 30.1 56.41 ± 41.03 65.97 ± 47.55
LDH, U/L
 ≤ 168.7 142.59 ± 16.72 146.24 ± 17.25
 > 168.7 206.02 ± 54.78 289.90 ± 353.72
GGT, U/L
 ≤ 26.9 16.52 ± 5.09 17.39 ± 5.02
 > 26.9 51.02 ± 45.46 55.67 ± 57.97
TBA, μmol/L
 ≤ 5.4 2.86 ± 1.25 3.21 ± 1.22
 > 5.4 12.76 ± 10.41 13.10 ± 8.99
ALP, U/L
 ≤ 80 61.72 ± 11.77 60.94 ± 10.51
 > 80 98.59 ± 25.85 120.26 ± 83.86
ALB, g/L
 ≤ 38.8 34.86 ± 3.74 36.16 ± 1.97
 > 38.8 42.56 ± 2.42 43.03 ± 2.48
TBIL, μmol/L
 ≤ 7.3 5.78 ± 1.26 5.98 ± 0.94
 > 7.3 13.11 ± 4.77 12.40 ± 4.78
ApoA1, g/L
 ≤ 1.1 0.96 ± 0.13 0.96 ± 0.12
 > 1.1 1.34 ± 0.19 1.33 ± 0.21
ApoB, g/L
 ≤ 1.1 0.84 ± 0.16 0.82 ± 0.16
 > 1.1 1.44 ± 0.79 1.17 ± 0.04
PT, S
 ≤ 11.9 11.11 ± 0.47 11.09 ± 0.52
 > 11.9 12.56 ± 0.67 12.95 ± 1.66
Fbg, g/L
 ≤ 3.6 2.63 ± 0.56 2.68 ± 0.54
 > 3.6 4.35 ± 0.67 4.27 ± 0.70
  1. Data are presented as mean (SD) or N (%)